MDLifespan Launches Advanced Serial Therapeutic Plasma Exchange Protocols at Cenegenics Beverly Hills
Photo Credit: MDLifespan
BEVERLY HILLS, Calif., March 4, 2026 (WELLNESS INTERVIEWS) — Medical technology company MDLifespan has announced the launch of its Advanced Serial Therapeutic Plasma Exchange (TPE) protocols at Cenegenics Beverly Hills.
Wellness Interviews
♾️
Wellness Interviews ♾️
The integration expands access to MDLifespan’s structured, multi-session outpatient plasma exchange protocols in the Los Angeles market. Therapeutic Plasma Exchange has historically been used in hospital settings for specific medical indications. MDLifespan adapts the technology into a standardized outpatient model designed to address environmental exposure concerns within physician-led care environments.
The company stated that the Beverly Hills integration strengthens its position as a provider of Advanced Serial Therapeutic Plasma Exchange protocols aimed at reducing inflammatory proteins and environmental toxins at the circulatory level.
“Southern California is a region where environmental exposure is part of the everyday health conversation. Our Advanced Serial Plasma Exchange protocols are structured, physician-supervised plans designed to support measurable reductions in circulating inflammatory burden while integrating with advanced biomarker analysis,” said Dr. Paul Savage, Founder and Chief Medical Officer of MDLifespan.
Los Angeles residents face environmental stressors including wildfire-related particulate exposure, urban air pollution, and increased public awareness around microplastics, PFAS, and chemical contaminants in water systems. The company noted that research continues to examine links between environmental toxins and systemic inflammation, contributing to patient interest in physician-directed strategies to evaluate and reduce circulating toxin burden.
Through the integration, Cenegenics Beverly Hills patients will have access to multi-session, physician-led plasma exchange protocols, targeted diagnostics focused on environmental toxin exposure, structured avoidance pathways designed to support reduction of systemic inflammatory load, and biomarker tracking to monitor progress over time.
Each protocol begins with diagnostic testing to assess toxin burden and key biomarkers, followed by a series of plasma exchange sessions. Patient progress is monitored through laboratory data.
MDLifespan stated that the Beverly Hills launch supports its national expansion strategy, which includes partnerships with physician-led clinics and integration into established performance health infrastructures to deliver standardized plasma exchange protocols.
For more information or to schedule a consultation, visit www.mdlifespan.com/cenegenics-consult.
Source: MDLifespan
